FRANKFURT (Reuters) – German healthcare conglomerate Fresenius SE & Co KGaA revved up the pace of its deals by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate agreement, the biosimilars unit of German peer Merck KGaA .